Anaphylaxis secondary to chymopapain.
Anaphylaxis occurs in approximately 1% of the patients treated with chymopapain. The incidence of anaphylaxis is ten times higher in women than in men. The severity of the reaction may be attenuated by pretreatment with H1- and H2-histamine receptor antagonist. Once anaphylaxis occurs, prompt and correct treatment must be instituted.